Table 2.
PSG variables in PD participants with and without EDS in Study 1
| PSG variables | PD-nEDS (n = 52) | PD-EDS (n = 25) | P-value |
|---|---|---|---|
| Total sleep time, min | 333.8 ± 111.3 | 381.8 ± 71.4 | 0.32 |
| Sleep latency, mina | 21.8 ± 25.9 | 11.7 ± 14.0 | 0.33 |
| WASO, min | 138.6 ± 85.0 | 98.0 ± 63.3 | 0.29 |
| Sleep efficiency, % | 72.4 ± 18.7 | 81.5 ± 11.7 | 0.22 |
| Wake, % | 27.6 ± 18.7 | 18.5 ± 11.7 | 0.22 |
| N1, % | 18.0 ± 11.0 | 17.4 ± 8.7 | 0.81 |
| N2, % | 58.8 ± 11.2 | 59.5 ± 11.3 | 0.60 |
| N3, % | 6.8 ± 7.9 | 5.3 ± 7.2 | 0.44 |
| REM sleep, % | 17.0 ± 9.3 | 19.3 ± 7.3 | 0.30 |
| REM sleep latency, min | 166.2 ± 97.9 | 153.7 ± 81.8 | 0.60 |
| AHIa | 7.0 ± 8.7 | 6.8 ± 6.2 | 0.62 |
| Mean O2 saturation | 94.9 ± 1.7 | 95.7 ± 1.4 | 0.19 |
| Minimum O2 saturation | 89.1 ± 4.1 | 90.6 ± 3.4 | 0.11 |
| Microarousal Index | 14.8 ± 7.6 | 17.3 ± 6.0 | 0.15 |
Results are expressed as mean ± standard deviation (Effect size when p < 0.05).
Since age and DA agonist (LEDD, mg) differed significantly between the two groups (p < 0.05), an analysis of covariance (ANCOVAs) was performed on each PSG variable using age and DA agonist (LEDD, mg) as covariables.
PD Parkinson’s disease, PD-EDS PD with excessive daytime sleepiness, PD-nEDS PD without EDS, PSG polysomnographic, DA dopamine, LEDD levodopa equivalent daily dosage, WASO wake after sleep onset, N1 non-rapid eye movement Sleep Stage 1, N2 non-rapid eye movement Sleep Stage 2, N3 non-rapid eye movement Sleep Stage 3. REM rapid eye movement.
aLog transformed.